PAI
SLNO

Palo Alto Investors’s Soleno Therapeutics SLNO Stock Holding History

Palo Alto Investors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,130
Closed -$220K – 39
2017
Q3 		$220K Sell
1,130
-4,520
-80% -$178K 0.01% 40
2017
Q2 		$212K Hold
5,650
– – 0.01% 38
2017
Q1 		$301K Buy
+5,650
New +$333K 0.01% 39

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Palo Alto Investors's SLNO Position: Q4 2017 in Review

Palo Alto Investors sold out of Soleno Therapeutics (SLNO) in Q4 2017, closing a stake of 1,130 shares — an estimated $220K sold.

Palo Alto Investors first reported a position in SLNO in Q1 2017 and held it in 3 quarters. The position peaked at $301K in Q1 2017. 11 funds tracked by Wall St. Rank hold SLNO as of Q4 2017.

  • Palo Alto Investors reported no remaining Soleno Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Palo Alto Investors sold 1,130 Soleno Therapeutics shares in Q4 2017, an estimated $220K.
  • Palo Alto Investors first reported a position in Soleno Therapeutics in Q1 2017 and held it in 3 quarters.
  • Palo Alto Investors's Soleno Therapeutics position peaked at $301K in Q1 2017.
  • 11 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2017.

Based on Palo Alto Investors's 13F filing for Q4 2017, filed 14 Feb 2018.